# Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)

> **NCT04318444** · PHASE2,PHASE3 · TERMINATED · sponsor: **Columbia University** · enrollment: 10 (actual)

## Conditions studied

- COVID-19
- Corona Virus Infection

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04318444
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-29
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The Institutional Review Board closed the study
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04318444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04318444, "Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04318444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*